PolyTherics joins Spirogen to develop antibody-drug conjugates

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Sino BioPharm to Acquire LaNova Medicines for $950.9 M Deal

LaNova Medicines, which happens to be a cancer drugmaker...

Rheumatoid Arthritis Treatment with Genetic Link Adds Hope

Researchers at the University of Edinburgh have gone on...

Sleep Lean Reviews – Is It Effective for Weight Loss?

Sleep Lean is a dietary supplement formulated for people...

CDSCO Moves to Online Submission for CGTP Trial Applications

As part of its continued efforts to streamline operations...

PolyTherics has executed a research collaboration deal with Spirogen to develop antibody-drug conjugates (ADCs) for the treatment of cancer.

Under the collaboration, the companies will produce ADCs by integrating PolyTherics’ proprietary TheraPEG linker technology with Spirogen’s pyrrolobenzodiazepines (PBDs) cytotoxic agents. The companies will then evaluate the potency of the resulting ADCs in preclinical models of cancer.

PolyTherics CEO John Burt said the developed antibody-drug conjugate reagents will have broad application for the development of ADCs as new cancer therapies. Spirogen CEO Chris Martin said PolyTherics’ TheraPEG conjugation technology will broaden the applications where the company’s PBD warheads and linkers can create potent ADC candidates.

Latest stories

Related stories

Sino BioPharm to Acquire LaNova Medicines for $950.9 M Deal

LaNova Medicines, which happens to be a cancer drugmaker...

Rheumatoid Arthritis Treatment with Genetic Link Adds Hope

Researchers at the University of Edinburgh have gone on...

Sleep Lean Reviews – Is It Effective for Weight Loss?

Sleep Lean is a dietary supplement formulated for people...

CDSCO Moves to Online Submission for CGTP Trial Applications

As part of its continued efforts to streamline operations...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back